Evidence map›Paper›PMID 39531328›Full record

ArticleJCI insight2024

Sphingosine 1-phosphate receptor 1signaling in macrophages reduces atherosclerosis in LDL receptor-deficient mice.

Francesco Potì, Enrica Scalera, Renata Feuerborn, Josephine Fischer, Lilli Arndt, Georg Varga, Evangelia Pardali, Matthias D Seidl, Manfred Fobker, Gerhard Liebisch and 10 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Anti-Inflammatory Interleukins in the Pathogenesis of Atherosclerosis.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Role of neutrophils in regulating vascular permeability in inflammatory and autoimmune diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Francesco PotìUnit of Neuroscience, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Enrica ScaleraDepartment of Food and Drug, University of Parma, Parma, Italy.
Renata FeuerbornCentral Laboratory Facility, University Hospital Münster, Münster, Germany.
Josephine FischerInstitute of Molecular Tumor Biology, University of Münster, Münster, Germany.
Lilli ArndtInstitute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Germany.
Georg VargaDepartment of Pediatric Rheumatology and Immunology, University Children's Hospital Münster, Münster, Germany.
Evangelia PardaliDepartment of Cardiology, University Hospital Münster, Münster, Germany.
Matthias D SeidlInstitute of Pharmacology and Toxicology, University of Münster, Münster, Germany.
Manfred FobkerCentral Laboratory Facility, University Hospital Münster, Münster, Germany.
Gerhard LiebischInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Bettina HesseDivision of General Internal Medicine, Nephrology, and Rheumatology, Department of Medicine D, and.
Alexander H LukaszDivision of General Internal Medicine, Nephrology, and Rheumatology, Department of Medicine D, and.
Jan RossaintDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
Beate E KehrelDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
Frank RosenbauerInstitute of Molecular Tumor Biology, University of Münster, Münster, Germany.
Thomas RennéInstitute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christina ChristoffersenDepartment of Clinical Biochemistry, Rigshospitalet, and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Manuela SimoniUnit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy.
Ralph BurkhardtInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Jerzy-Roch NoferUnit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sphingosine 1-phosphate (S1P) is a lysosphingolipid with antiatherogenic properties, but mechanisms underlying its effects remain unclear. We here investigated atherosclerosis development in cholesterol-rich diet-fed LDL receptor-deficient mice with high or low overexpression levels of S1P receptor 1 (S1P1) in macrophages. S1P1-overexpressing macrophages showed increased activity of transcription factors PU.1, interferon regulatory factor 8 (IRF8), and liver X receptor (LXR) and were skewed toward an M2-distinct phenotype characterized by enhanced production of IL-10, IL-1RA, and IL-5; increased ATP-binding cassette transporter A1- and G1-dependent cholesterol efflux; increased expression of MerTK and efferocytosis; and reduced apoptosis due to elevated B cell lymphoma 6 and Maf bZIP B. A similar macrophage phenotype was observed in mice administered S1P1-selective agonist KRP203. Mechanistically, the enhanced PU.1, IRF8, and LXR activity in S1P1-overexpressing macrophages led to downregulation of the cAMP-dependent PKA and activation of the signaling cascade encompassing protein kinases AKT and mTOR complex 1 as well as the late endosomal/lysosomal adaptor MAPK and mTOR activator 1. Atherosclerotic lesions in aortic roots and brachiocephalic arteries were profoundly or moderately reduced in mice with high and low S1P1 overexpression in macrophages, respectively. We conclude that S1P1 signaling polarizes macrophages toward an antiatherogenic functional phenotype and countervails the development of atherosclerosis in mice.

Indexed as

AtherosclerosisMacrophagesReceptors, LDLSignal TransductionAnimalsApoptosisATP Binding Cassette Transporter 1Cholesterolc-Mer Tyrosine KinaseDisease Models, AnimalLiver X ReceptorsLysophospholipidsMaleMiceMice, Inbred C57BLMice, KnockoutAbca1 protein, mouseATP Binding Cassette Transporter 1Cholesterolc-Mer Tyrosine KinaseLiver X ReceptorsLysophospholipidsMertk protein, mouseProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Receptors, LDLS1pr1 protein, mouseSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate ReceptorsTrans-ActivatorsAtherosclerosisInflammationLipoproteinsMacrophagesVascular biology

Identifiers

PMID39531328
PMCPMC11665566

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.